Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: A population-based cohort study

Annals of the Rheumatic Diseases

Volumn 74, Issue 2, 2015, Pages 326-332

  Ogdie, Alexis ^a   Yu, YiDing ^b,c   Haynes, Kevin ^a   Love, Thorvardur Jon ^d   Maliha, Samantha ^e   Jiang, Yihui ^a   Troxel, Andrea B ^a   Hennessy, Sean ^a   Kimmel, Steven E ^f   Margolis, David J ^f   Choi, Hyon ^g   Mehta, Nehal N ^h   Gelfand, Joel M ^a,f  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ICELAND   (Iceland)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETRETIN; ETRETINATE; HYDROXYUREA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PSORALEN; RETINOID; ANTIRHEUMATIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; OUTCOME ASSESSMENT; PHOTOTHERAPY; POPULATION BASED CASE CONTROL STUDY; PRIMARY MEDICAL CARE; PSORIASIS; PSORIATIC ARTHRITIS; RADIOTHERAPY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; ULTRAVIOLET RADIATION; ADOLESCENT; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COMPLICATION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; YOUNG ADULT;

EID: 84921457520     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2014-205675     Document Type: Article

References (51)

1. Koolaee RM, Takeshita J, Ogdie A. Epidemiology and natural history of psoriatic arthritis: an update. Curr Derm Rep 2013;2:66-76.
2. Ogdie A, Langan S, Love T, et al. Prevalence and treatment patterns of psoriatic arthritis in the United Kingdom. Rheumatology 2013;52:568-75.
3. Jamnitski A, Symmons D, Peters MJL, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis 2013;72:211-16.
4. Gladman DD, Ang M, Su L, et al. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 2009;68:1131-5.
5. Ahlehoff O, Gislason G, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011;270:147-57.
6. Li W, Han J, Manson J, et al. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol 2012;166:811-18.
7. Chin Y, Yu H, Li W, et al. Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study. J Eur Acad Dermatol Venereol 2013;27:1262-68.
8. Ahlehoff O, Gislason G, Jorgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish Nationwide Cohort Study. Eur Heart J 2012;33:2054-64.
9. Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 2009;129:2411-18.
10. Gelfand J, Neimann A, Shin D, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-42.
11. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011;70:929-34.
12. Lindhardsen J, Gislason GH, Jacobsen S, et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2014;73:1515-21.
13. Mehta NN, Azfar RS, Shin DB, et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-6.
14. Meune C, Touzé E, Trinquart L, et al. High risk of clinical cardiovascular events in rheumatoid arthritis: Levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis 2010;103:253-61.
15. Gabriel S. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 2008;121(10 Suppl 1):S9-S14.
16. Armstrong E, Harskamp C, Armstrong A. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc 2013;2:e000062.
17. Ogdie A, Haynes K, Troxel A, et al. Mortality in patients with psoriatic arthritis compared to patients with rheumatoid arthritis, psoriasis alone, and the general population. Ann Rheum Dis 2014;73:149-53.
18. Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med 2008;121(10 Suppl 1):S21-31.
19. Wilson P. Evidence of systemic inflammation and estimation of coronary artery disease risk: a population perspective. Am J Med 2008;121(10 Suppl 1):S15-20.
20. Ogdie A, Langan S, Parkinson J, et al. Medical record databases. In: Strom B, Kimmel S, Hennessy S. eds. Pharmacoepidemiology, 5th edn. Oxford, UK: Wiley-Blackwell, 2012:224-43.
21. Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401.
22. Cegedim Strategic Data. The Health Improvement Network: Our Data. 2013(Oct 2).
23. Doran T, Fullwood C, Gravelle H, et al. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med 2006;335:375-84.
24. Chishom J. The Read clinical classification. BMJ 1990;300:1092.
25. Seminara NM, Abuabara K, Shin DB, et al. Validity of The Health Improvement Network (THIN) for the study of psoriasis. Br J Dermatol 2011;164:602-9.
26. Garcia Rodriguez LA, Tolosa LB, Ruigomez A, et al. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol 2009;38:173-7.
27. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196-202.
28. Watson DJ, Rhodes T, Bing C, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002;162:1105-10.
29. Ogdie A, Alehashemi S, Love T, et al. Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in The Health Improvement Network. Pharmacoepidemiol Drug Saf 2014;23:918-22.
30. Dubreuil M, Hee Rho Y, Man D, et al. The independent impact of psoriatic arthritis and rheumatoid arthritis on diabetes incidence: A UK Population-Based Cohort Study. Rheumatology (Oxford) 2014;53:346-52.
31. Love T, Zhu Y, Zhang Y, et al. Obesity and the risk of psoriatic arthritis: a population-based study. Ann Rheum Dis 2012;71:1273-7.
32. Hammad T, Feight A, Iyasu S, et al. Determining the predictive value of Read/OXMIS codes to identify incident acute myocardial infarction in the General Practice Research Database. Pharmacoepidemiol Drug Saf 2008;17:1197-201.
33. Giast D, Wallander M, Gonzalez-Perez A, et al. Incidence of hemorrhagic stroke in the general population: validation of data from The Health Improvement Network. Pharmacoepidemiol Drug Saf 2013;22:176-82.
34. Ruigomez A, Martin-Merino E, Rodriguez L. Validation of ischemic cerebrovascular diagnoses in the health improvement network (THIN). Pharmacoepidemiol Drug Saf 2010;19:579-85.
35. Kochanek K, Xu J, Murphy S, et al. Deaths: Final Data for 2009. Natl Vital Stat Rep 2011;60:1-116.
36. Office of National Statistics. Mortality statistics Metadata 2013(Oct 16).
37. Cegedim Strategic Data. THIN Data Quality Assurance. 2013(Oct 2).
38. Hall GC. Validation of death and suicide recording on THIN UK primary care database. Pharmacoepidemiol Drug Saf 2009;18:120-31.
39. Haynes K, Bilker WB, Tenhave TR, et al. Temporal and within practice variability in the health improvement network. Pharmacoepidemiol Drug Saf 2011;20:948-55.
40. Maguire A, Blak B, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 2009;18:76-83.
41. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987;40:373-83.
42. Bursac Z, Gauss CH, Williams DK, et al. Purposeful selection of variables in logistic regression. Source Code Biol Med 2008;3:17.
43. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 2007;18:800-4.
44. UK National Statistics. UK National Statistics for MI and Stroke-Table 2.1. 2013 (Oct 8).
45. Yeung H, Takeshita J, Mehta NN, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013;149:1173-9.
46. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2013;273:197-204.
47. Smolen J, Landewé R, Breedveld F, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic andbiological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
48. van Halm V, Nurmohamed M, Twisk J, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk forcardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006;8:R151.
49. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf 2013;22:559-70.
50. National Institute for Health and Care Excellence. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. http://www.nice.org.uk/guidance/ta199 (accessed 20 Oct 2014).
51. Mease P, Gladman D, Papp K, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 2013;69:729-35.